Select therapeutic use:
Indications for REYATAZ ORAL POWDER:
HIV-1 infection, in combination with other antiretroviral agents.
Use other form.
See full labeling. Mix with food (eg, applesauce, yogurt) or beverage (eg, milk, infant formula, water). <3mos (<5kg): not recommended. ≥3mos (5 to <15kg): atazanavir 200mg (4 packets) + ritonavir oral solution 80mg; (15 to <25kg): atazanavir 250mg (5 packets) + ritonavir oral solution 80mg; (≥25kg who are unable to swallow caps): atazanavir 300mg (6 packets) + ritonavir oral solution 100mg; all: single daily dose.
Concomitant alfuzosin, rifampin, irinotecan, lurasidone (if Reyataz co-administered with ritonavir), pimozide, triazolam, oral midazolam, ergots, cisapride, elbasvir/grazoprevir, glecaprevir/pibrentasvir, St. John's wort, lovastatin, simvastatin, sildenafil (for PAH), indinavir, nevirapine.
Assess CrCl, SCr, urinalysis with microscopic exam prior to initiation and during therapy; consider discontinuing if progressive kidney disease develops. ESRD with hemodialysis in treatment-experienced or severe hepatic impairment: not recommended. Preexisting or at high risk for renal disease: consider alternatives. Cardiac conduction abnormalities; consider ECG monitoring if preexisting marked 1st-degree AV block or 2nd/3rd-degree AV block. Consider interruption or discontinuation if nephrolithiasis or cholelithiasis occurs. Liver disease, hepatitis B and/or C, marked elevations in transaminases: monitor LFTs before and during therapy. Consider alternative if jaundice or scleral icterus occurs. Diabetes. Hemophilia. Elderly. Pregnancy. Nursing mothers: not recommended.
HIV-1 protease inhibitor.
See Contraindications. Concomitant other protease inhibitors (excluding ritonavir and saquinavir), sofosbuvir/velpatasvir/voxilaprevir, salmeterol: not recommended. Avoid atazanavir + ritonavir with boceprevir, fluticasone, voriconazole. Concomitant paclitaxel, repaglinide, carbamazepine, phenytoin, phenobarbital, bosentan, or buprenorphine without ritonavir: not recommended. Caution with UGT1A1 or CYP3A substrates (eg, IV midazolam, CCBs, statins [eg, atorvastatin, rosuvastatin (max 10mg/day); use lowest dose necessary], PDE5 inhibitors: reduce doses of these to treat ED; max 25mg sildenafil in 48hrs; max 2.5mg vardenafil in 24hrs or 72hrs [atazanavir + ritonavir]; max 10mg tadalafil in 72hrs; tadalafil to treat PAH [see full labeling]). May be antagonized by CYP3A inducers. Consider reducing diltiazem or clarithromycin dose by 50%; rifabutin dose by 75%. Antagonized by H2-blockers (see full labeling). Give PPIs 12hrs before atazanavir + ritonavir; avoid in therapy-experienced. Give 2hrs before or 1hr after antacids, buffered or enteric coated didanosine. Antagonized by efavirenz, bosentan, tenofovir DF (see dose). Potentiates saquinavir, trazodone, fluticasone, ketoconazole, itraconazole, buprenorphine (reduce dose), colchicine (esp. renal or hepatic impaired; do not use), quetiapine (if co-administration needed, reduce quetiapine dose to 1/6 of current dose). Affects oral contraceptives; use alternative non-hormonal methods. Monitor antiarrhythmics, warfarin, tricyclics, rifabutin, immunosuppressants. See full labeling.
Nausea, vomiting, diarrhea, abdominal pain, jaundice, scleral icterus, rash (may be severe; discontinue if occurs), headache, insomnia, peripheral neuropathy, dizziness, myalgia, depression, fever, hyperglycemia, fat redistribution, immune reconstitution syndrome, hyperbilirubinemia, nephrolithiasis/cholelithiasis, chronic kidney disease, 2nd- or 3rd-degree AV block. Children: also cough, peripheral edema, extremity pain, nasal congestion, oropharyngeal pain, wheezing, rhinorrhea.
Register pregnant patients exposed to atazanavir by calling (800) 258-4263. See Norvir entry in this section for more information on ritonavir.
Caps 150mg, 200mg—60; 300mg—30; Oral powder—30